Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04590963 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04590963 · ClinicalTrials.gov record · last posted 2026-06-01

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Name: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer — clinical trial record (NCT04590963)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: INTERLINK-1

StatusActive, Not Recruiting

PhasePhase 3

SponsorAstraZeneca

Started2020-10-02

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer

Amendment record 37 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 37 times since 2020-10-12; most recent amendment 2026-05-28. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-10-21

Status change Recruiting→Active, Not Recruitingv23

Trial Details

NCT Number	NCT04590963
Lead Sponsor	AstraZeneca Collaborators: Innate Pharma
Conditions	Squamous Cell Carcinoma of the Head and Neck
Enrollment	370 participants
Start Date	2020-10-02
Primary Completion	2022-05-11 (estimated)
Study Completion	2026-09-24 (estimated)
Updated on ClinicalTrials.gov	2026-06-01